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January 2021Despite advances in therapeutic strategies, acute myo-
cardial infarction (AMI) patients remain at high risk for
recurrent ischemic events. Approximately 60% of recur-
rent cardiovascular (CV) events (CV death, MI, or stroke)
from the first year occur within the first 90 days following
the index event.1 The overwhelming body of data with
current low-density lipoprotein–directed therapies con-
sistently demonstrates a reduction in recurrent CV events
in the chronic phase, although risk remains high despite
intensive statin therapy in the very early period following
an AMI.2-6 Morbidity and mortality associated with both
the index coronary event and recurrent CV events are as
high as 20% per year.7,8 Therefore, there remains a
critical unmet need for effective and safe therapies that
target the high-risk period that immediately follows AMI.
Reverse cholesterol transport removes excess choles-
terol from arteries containing atherosclerotic plaque and
transports it to the liver for excretion.9,10 The first step in
this process is known as cholesterol efflux and is
mediated in part by apolipoprotein A-I (apoA-I), the
chief protein component of high-density lipoprotein
(HDL).11 Cholesterol efflux is associated with CV events
independent of other traditional risk factors.12-15 Addi-
tionally, cholesterol efflux has demonstrated an inverse
correlation with all-cause mortality among ST-elevation
myocardial infarction (STEMI) patients.16 Subsequent to
an acute coronary syndrome (ACS) event, cholesterol
efflux is reduced, with lowest levels around 2 to 5 days
before returning to baseline approximately 30 days after
an event.17-19 During the acute phase response following
an ACS event, the protein cargo of native HDL particles
may be altered or lipids may be oxidized, rendering HDL
efflux capacity less efficient. A novel infusible human
plasma-derived apoA-I that robustly elevates cholesterol
efflux with relatively modest increases in apoA-I may be
less susceptible to such acute phase modification and
might retain functionality during this time period.
Therefore, it has been suggested that pharmacotherapies
which increase apoA-I and elevate cholesterol efflux
capacity may be beneficial among post-AMI patients.20
Promotion of cholesterol efflux has been observed with
infusions of previous formulations of apoA-I.21 MDCO-
216, a recombinant dimeric ApoA-I Milano, a mutant form
of apoA-I, demonstrated an 80% increase in ATP-binding
cassette A1 (ABCA1)–dependent cholesterol efflux com-
pared to placebo.22 CER-001, a bioengineered recombi-
nant of wild-type apoA-I, demonstrated a 6% increase in
ABCA1-dependent cholesterol efflux.23 However, in
randomized placebo-controlled coronary imaging studies,
both formulations failed to demonstrate short-term
plaque reduction compared to placebo.22,24 In contrast,
CSL112, a novel intravenous formulation of native apoA-I
purified from human plasma developed for use in patients
with ACS to reduce the risk of CV death, MI, and stroke,
demonstrated more favorable pharmacodynamic (PD)properties compared to MDCO-216 and CER-001, with an
increase in ABCA1-dependent cholesterol efflux by
approximately 330%.21 , 25 It should be noted that
although the methods used to measure cholesterol efflux
were similar, there are no direct head-to-head compari-
sons of these agents.
Substantial differences exist between the 3 apoA-I
formulations. Mutant ApoA-I Milano in MDCO-216 was
shown to promote catabolism of endogenous apoA-I,22
which has not been observed with other formulations. All
3 formulations differ in type and amount of phospholipids
used, which are important because different lipid
combinations affect the ability of HDL to promote
cholesterol efflux.26 Additionally, CSL112 elevates leci-
thin cholesterol acyltransferase activity, which is respon-
sible for the esterification of cholesterol, an important
step in reverse cholesterol transport because it allows for
a greater load to cholesterol to be transported.27
Esterification of cholesterol is inhibited with MDCO-
216, and the phospholipid component of CER-001 may
lead to impaired cholesterol esterification.28,29
A total of 1060 participants have received at least 1
infusion of CSL112 in 7 completed studies. A phase 2b
study in AMI participants demonstrated an immediate
and dose-dependent 2.06-fold rise in apoA-I plasma
concentrations after the initial 6-g CSL112 infusion
followed by a gradual return to baseline over approxi-
mately 5-7 days.25 Additionally, a rapid increase in HDL-C
and significant dose-dependent elevations in pre-β HDL
and global cholesterol effluxwere notedwith CSL112.30 ,
31 A third phase 1 study was conducted in adults with
normal renal function and moderate renal impairment
(chronic kidney disease stage 3), which confirmed that a
dose adjustment was not needed for impaired renal
function.30 ,32 A phase 2a clinical trial in participants
with stable atherosclerotic disease demonstrated that a
single CSL112 infusion was well tolerated and caused an
immediate increase in cholesterol efflux capacity and
apoA-I levels.33 The phase 2b study in AMI participants
with normal ormildly impaired renal function at high risk
of subsequent CV events demonstrated that administra-
tion of 4 weekly infusions of CSL112 was well tolerated
with no significant change in liver or kidney function.
Acute enhancement of cholesterol efflux and apoA-I was
also observed.25 Results were similar in a subsequent
third phase 2 study among participants with AMI and
moderate renal impairment.34
This manuscript describes the AEGIS-II trial
(ClinicalTrials.gov NCT03473223), a phase 3, multicen-
ter, double-blind, randomized, placebo-controlled,
parallel-group trial designed to investigate whether
CSL112 can safely reduce the risk of major adverse CV
events (MACE) through 90 days, a period of unmet
clinical need. High-risk post-AMI participants with multi-
vessel coronary artery disease are being enrolled.




This trial, funded by CSL Behring, was collaboratively
designed by members of the executive committee and
the sponsor. Executive and steering committees, chaired
by Dr C. Michael Gibson, are responsible for trial conduct
and oversight. The executive committee is comprised of
principal investigators and other recognized leaders in
the field of ACS, lipidology, and biostatistics, and a
representative of the sponsor.
An unblinded Independent Data and Monitoring
Committee (IDMC), consisting of qualified scientists not
affiliated with investigators or the sponsor, was selected
by the executive committee. The IDMC is responsible for
the following: review of safety data at planned intervals
and identifying any safety concerns that arise during the
course of the study, review of efficacy and safety data
during prespecified interim analyses for futility and
efficacy, requesting an interim safety review if needed,
monitoring any potential risk of an immune response to
CSL112 and apoA-I and recommending the number of
samples to be assayed, and providing recommendations
regarding study conduct including study progression and
termination. Additionally, the IDMC will monitor un-
blinded suspected MACE and other safety data.
An independent Clinical Events Committee (CEC) will
review and adjudicate all suspected MACE outcomes
while blinded to treatment assignment. The occurrence
of potential hepatic injury based on laboratory tests
(alanine aminotransferase and total bilirubin), clinical
assessments, and new or worsening heart failure events
will also be reviewed and adjudicated in a blinded
fashion.
Study objectives
The primary objective of the study is to evaluate the
efficacy of 4 weekly infusions of CSL112 on reducing
MACE compared with placebo in participants with AMI.
Study population and patient selection
Patients eligible for enrollment include adults at least
18 years of age with type 1 (spontaneous) MI defined by
the Third Universal Definition of MI,35-37 with multivessel
coronary artery disease defined as ≥50% stenosis on 2 or
more epicardial artery territories or the left main artery
during a prior cardiac catheterization or cardiac cathe-
terization during the index ACS event, or prior percuta-
neous coronary intervention (PCI) and ≥50% stenosis of
at least 1 epicardial artery territory different from the
prior revascularized artery, or prior multivessel coronary
bypass grafting. Additionally, participants must have the
presence of established CV risk factor(s), defined as
pharmacologic treatment for diabetes mellitus, or at least
2 of the following: age ≥ 65 years, prior history of MI, or
peripheral arterial disease (PAD).Key exclusion criteria include (1) ongoing hemody-
namic instability defined as New York Heart Association
Class III or IV heart failure within the last year, Killip Class
III or IV, sustained or symptomatic hypotension (systolic
blood pressure <90 mm Hg), or left ventricular ejection
fraction <30%; (2) evidence of hepatobiliary disease
defined as active hepatic dysfunction or active biliary
obstruction, chronic cirrhosis or infectious or inflamma-
tory hepatitis, or alanine aminotransferase >3× the upper
limit of normal or total bilirubin >2× the upper limit of
normal; (3) evidence of severe chronic kidney disease
defined as estimated glomerular filtration rate <30 mL/
min/1.73 m2 calculated with the Chronic Kidney Disease
Epidemiology Collaboration equation; (4) scheduled
coronary bypass graft surgery after randomization; and
(5) body weight <50 kg.
All participants undergoing angiography, and thereby
exposed to intravenous contrast, must demonstrate
stable renal function at least 12 hours after contrast
exposure, defined as an increase in serum creatinine of
<0.3 mg/dL from the precontrast serum creatinine value.
A full detailed list of the inclusion and exclusion criteria
can be found in Supplemental Table I.
Randomization and study drug protocol
Enrolled participants will be stratified by index MI type
(STEMI vs non–STEMI), management of index MI (PCI vs
medical management), and region (North America, Latin
America, Western Europe, Central and Eastern Europe,
Asia Pacific) and then randomized using Interactive
Response Technology in a 1:1 ratio to receive either 6 g
CSL112 or placebo. The placebo being used in the trial is
a diluted form of albumin (25% albumin diluted to 4.4%)
that is similar in color and foaming properties to CSL112
and will be given in the same volume as the active
treatment to maintain the blinding principles of the study.
The 6-g dose of CSL112 was chosen based on the renal
and hepatic safety profile in the AEGIS-I and
CSL112_2001 trials, as well as pharmacokinetic (PK)-PD
models demonstrating the relationship between 6 g
CSL112 and apoA-I exposure and cholesterol efflux
capacity, derived from AEGIS-I data.25,34,38 Published
animal and human studies have demonstrated that
elevation of plasma apoA-I can produce strong reduction
of plaque cholesterol in an interval as short as 1 week.39,
40 All participants will receive 4 consecutive weekly
intravenous infusions of study drug, with infusions
occurring approximately 5 to 8 days apart during the
active treatment period. First infusion will be given on or
before the day of hospital discharge and within 5 days of
presentation to the hospital for evaluation and treatment
of the index MI. All 4 infusions will be administered
within 30 days of the first infusion, during this period of
high risk for a recurrent cardiovascular event. A detailed
overview of the design and timeline of the study is
presented in Figure 1.
Figure 1
Study design and timeline.FMC, first medical contact.
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Study assessments will occur at screening, before and
after each infusion visit, and at the end of the active
treatment period. Follow-up study assessments will occur
at day 60 and day 90 and then every 90 days until day 365.
Study conclusion will occur at least 365 days after the last
subject is randomized (Figure 1).
The primary efficacy outcome is the time to first
occurrence of the MACE composite of CV death, MI, or
stroke from the time of randomization through 90 days.
All MI types are included in the primary end point.
Key secondary outcomes, which further explore the
efficacy of CSL112, include the total number of hospital-
izations for coronary, cerebral, or peripheral ischemia
from the time of randomization through 90 days, and
time to first occurrence of the composite of CV death, MI,
or stroke from the time of randomization through
180 days and through 365 days.
Other secondary outcomes include time to first
occurrence of each component of the primary efficacy
composite separately (CV death, MI, and stroke) from
time of randomization through 90 days; time to first
occurrence of CV death, type 1 MI, or stroke from the
time of randomization through 90, 180, and 365 days; as
well as time to occurrence of all-cause death from time of
randomization through 365 days. Secondary outcomes
assessing safety include the number of participants with
adverse events through 90 days, treatment-related ad-
verse events through the end of study, and serious
adverse events through the end of study. Additionally,
changes in clinical laboratory assessments from baseline
will be described. A full list of study outcomes, includingexploratory outcomes, which assess the efficacy of
CSL112 throughout various time periods and on the
total burden of disease, examine medical resource
utilization, and characterize the PK profile of CSL112,
can be found in Supplemental Table II.
Analysis populations
Efficacy analyses will be completed in the intent-to-treat
population which includes all participants randomized to
receive either CSL112 or placebo, and analyses will be
conducted according to the randomized treatment group,
regardless of the treatment actually received. All safety
analyses will be completed in the safety population
which contains all randomized participants who received
at least a partial dose of study drug, and analyses will be
based on the treatment the subject actually receives.Statistical considerations
Final sample size will be based on CEC-adjudicated
MACE rates, which will be monitored throughout the
enrollment phase. Sample size was calculated assuming
CSL112 will have a 20% relative risk reduction (hazard
ratio = 0.80) compared to placebo in the primary
outcome through 90 days of follow-up after randomiza-
tion. Assuming a 1-sided α of .025, 1,004 confirmed
MACE events will provide at least 90% power. It is
estimated that approximately 17,400 participants will be
enrolled, assuming no dropouts and a 90-day placebo
event rate of 6.4%. Sample size calculation takes into
account 3 planned interim analyses performed at 30%,
50%, and 70% of the target number of CEC-adjudicated
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respectively).
Sample size adjustment will be based on blinded event
rates pooled across both randomized groups. Permissible
sample sizes range from a minimum of 15,000 to a
maximum of 20,600 participants.
The first and second interim analyses will assess futility,
and the third interim analysis will assess efficacy. The
futility boundary is based on 2-sided 95% CI and specifies
that no underlying treatment difference exists if the lower
boundary of the confidence interval excludes a hazard
ratio of 0.80. The efficacy stopping boundary is set at a
hazard ratio < 0.753 (1-sided .000083 α level) using an α
spending function from the Ρ family with a parameter
value of 16. If the primary null hypothesis is not rejected
at the interim efficacy analysis, a 1-sided α level of
.024999 at the final analysis will be used. Actual
significance level will be recomputed using an α
spending function at the time of analysis if the observed
numbers of events are different from those expected.
Cumulative event rates using the Kaplan-Meier method
will be calculated for the primary efficacy outcome
according to the randomized treatment group. A covar-
iate adjusted Cox regression model including fixed effects
for treatment, region, index MI type, index MI manage-
ment, age, diabetes, PAD, prior MI, and an interaction
term for index MI type and index MI management will be
fitted to estimate the hazard ratio and 2-sided 95% CI, as
well as a 1-sided Wald P value (P < .025 for significance).
Key secondary outcomes will be tested using a 1-sided
.025 significance level, adjusted for multiplicity. Time to
first occurrence of CV death, MI, or stroke through 180
and 365 days will be compared by treatment using the
same methods as the primary efficacy outcome analysis.
Mean rate of hospitalization for coronary, cerebral, or
peripheral ischemia per 90 days will be reported by
planned treatment group. Groups will be compared using
a negative binomial regression model with fixed effects
for treatment, region, index MI type, index MI manage-
ment, age, diabetes, PAD, prior MI, and an interaction
term for index MI type and index MI management, as well
as the log-transformed duration of follow-up within
90 days. The log link function will be used, and a 1-
sided P value as well as the rate ratio (CSL112:placebo)
and its 2-sided 95% CI will be reported.
Multiplicity is adjusted for in 2 ways. Inflation of type I
error due to the interim efficacy analysis will be
controlled using an α spending function from the P
family as described. Multiplicity concerns from testing
the primary and key secondary end points will be
addressed using a serial gatekeeping procedure41 for 3
defined families of null hypotheses to control the overall
error rate at a 1-sided .025 level. If the primary null
hypothesis (first family of hypothesis) is rejected,
hypotheses associated with the second family will be
tested using the Hochberg procedure at a 1-sided .025type 1 error level. If both family 2 null hypotheses are
rejected, testing will proceed to the family 3 at a 1-sided
.025 level. If significance is not achieved at any step of the
procedure, the formal testing process stops and any
remaining secondary outcomes will be considered
exploratory. A table of the 3 defined families of the null
hypotheses for the serial gatekeeping procedure can be
found in Supplemental Table III.
Protocol amendment
During the course of the study, it was noted that the
blinded aggregate primary end point event rates were
lower than anticipated. Therefore, 2 major changes were
implemented that did not fundamentally alter the study
purpose or patient population. The first was to enhance
the risk profile of the study population to require patients
to have either pharmacologically treated diabetes mellitus
or any 2 or more of the other established risk factors
(age ≥ 65 years, prior MI, or peripheral arterial disease)
versus the original requirement that subjects have only 1
of these risk factors. The second modification was to
expand the definition of MI within the composite primary
end point to include all MIs and not just type 1 MIs as
originally designed. In recognition of the limitations in
the classification of MI in subtypes, which is largely based
on subjective assessment, especially when distinguishing
between type 1 and type 2, the aim was to reduce a
potentially negative impact on sensitivity and misclassi-
fication in accounting for MI in the primary end point.42
Conclusions
The AEGIS-II trial is phase 3, multicenter, double-blind,
randomized, placebo-controlled, parallel-group study
designed to investigate the efficacy and safety of 4
weekly CSL112 infusions on short-term rates of recurrent
CV events among post-AMI participants. Higher choles-
terol efflux capacity is associated with a lower risk of
cardiovascular events, and CSL112 improves cholesterol
efflux. This phase 3 trial will test in turn whether CSL112
therefore improves the time to first occurrence of the
composite of CV death, MI, or stroke through 90 days.
Key secondary outcomes include the total number of
hospitalizations for coronary, cerebral, or peripheral
ischemia through 90 days, as well as time to first
occurrence of the primary efficacy composite through
180 and 365 days. Additional information on CSL112’s
safety and PK/PD profile, including cholesterol efflux
measurements, will also be collected. Participant enroll-
ment began in March 2018.Author statement
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